Type III CRISPR-Cas systems can provide redundancy to counteract viral escape from type I systems

  1. Sukrit Silas
  2. Patricia Lucas-Elio
  3. Simon A Jackson
  4. Alejandra Aroca-Crevillén
  5. Loren L Hansen
  6. Peter C Fineran
  7. Andrew Z Fire  Is a corresponding author
  8. Antonio Sánchez-Amat  Is a corresponding author
  1. Stanford University, United States
  2. Universidad de Murcia, Spain
  3. University of Otago, New Zealand
  4. Stanford University School of Medicine, United States

Abstract

CRISPR-Cas-mediated defense utilizes information stored as spacers in CRISPR arrays to defend against genetic invaders. We define the mode of target interference and role in antiviral defense for two CRISPR-Cas systems in Marinomonas mediterranea. One system (type I-F) targets DNA. A second system (type III-B) is broadly capable of acquiring spacers in either orientation from RNA and DNA, and exhibits transcription-dependent DNA interference. Examining resistance to phages isolated from Mediterranean seagrass meadows, we found that the type III-B machinery co-opts type I-F CRISPR-RNAs. Sequencing and infectivity assessments of related bacterial and phage strains suggests an "arms race" in which phage escape from the type I-F system can be overcome through use of type I-F spacers by a horizontally-acquired type III-B system. We propose that the phage-host arms race can drive selection for horizontal uptake and maintenance of promiscuous type III interference modules that supplement existing host type I CRISPR-Cas systems.

Data availability

The following data sets were generated
The following previously published data sets were used

Article and author information

Author details

  1. Sukrit Silas

    Chemical and Systems Biology, Stanford University, Stanford, United States
    Competing interests
    The authors declare that no competing interests exist.
  2. Patricia Lucas-Elio

    Genetics and Microbiology, Universidad de Murcia, Murcia, Spain
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-7182-1189
  3. Simon A Jackson

    Microbiology and Immunology, University of Otago, Dunedin, New Zealand
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-4512-3093
  4. Alejandra Aroca-Crevillén

    Genetics and Microbiology, Universidad de Murcia, Murcia, Spain
    Competing interests
    The authors declare that no competing interests exist.
  5. Loren L Hansen

    Pathology, Stanford University, Stanford, United States
    Competing interests
    The authors declare that no competing interests exist.
  6. Peter C Fineran

    Microbiology & Immunology, University of Otago, Dunedin, New Zealand
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-4639-6704
  7. Andrew Z Fire

    Pathology and Genetics, Stanford University School of Medicine, Stanford, United States
    For correspondence
    afire@stanford.edu
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-6217-8312
  8. Antonio Sánchez-Amat

    Genetics and Microbiology, Universidad de Murcia, Murcia, Spain
    For correspondence
    antonio@um.es
    Competing interests
    The authors declare that no competing interests exist.

Funding

National Institutes of Health (R01-GM37706)

  • Andrew Z Fire

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Copyright

© 2017, Silas et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 3,325
    views
  • 478
    downloads
  • 82
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Sukrit Silas
  2. Patricia Lucas-Elio
  3. Simon A Jackson
  4. Alejandra Aroca-Crevillén
  5. Loren L Hansen
  6. Peter C Fineran
  7. Andrew Z Fire
  8. Antonio Sánchez-Amat
(2017)
Type III CRISPR-Cas systems can provide redundancy to counteract viral escape from type I systems
eLife 6:e27601.
https://doi.org/10.7554/eLife.27601

Share this article

https://doi.org/10.7554/eLife.27601

Further reading

    1. Biochemistry and Chemical Biology
    2. Microbiology and Infectious Disease
    Qian Wang, Jinxin Liu ... Qian Liu
    Research Article

    Paramyxovirus membrane fusion requires an attachment protein for receptor binding and a fusion protein for membrane fusion triggering. Nipah virus (NiV) attachment protein (G) binds to ephrinB2 or -B3 receptors, and fusion protein (F) mediates membrane fusion. NiV-F is a class I fusion protein and is activated by endosomal cleavage. The crystal structure of a soluble GCN4-decorated NiV-F shows a hexamer-of-trimer assembly. Here, we used single-molecule localization microscopy to quantify the NiV-F distribution and organization on cell and virus-like particle membranes at a nanometer precision. We found that NiV-F on biological membranes forms distinctive clusters that are independent of endosomal cleavage or expression levels. The sequestration of NiV-F into dense clusters favors membrane fusion triggering. The nano-distribution and organization of NiV-F are susceptible to mutations at the hexamer-of-trimer interface, and the putative oligomerization motif on the transmembrane domain. We also show that NiV-F nanoclusters are maintained by NiV-F–AP-2 interactions and the clathrin coat assembly. We propose that the organization of NiV-F into nanoclusters facilitates membrane fusion triggering by a mixed population of NiV-F molecules with varied degrees of cleavage and opportunities for interacting with the NiV-G/receptor complex. These observations provide insights into the in situ organization and activation mechanisms of the NiV fusion machinery.